Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in:

25-11-2025 | Lymphoma of the Central Nervous System | Review

Advances in Primary Central Nervous System Lymphoma

Authors: Kate E. Therkelsen, Antonio Omuro

Published in: Current Neurology and Neuroscience Reports | Issue 1/2025

Login to get access

Abstract

Purpose of Review

Optimal initial management can have a significant impact in long-term outcome in primary CNS lymphoma. This article reviews recent advances and the state of the field.

Recent Findings

Genomic analysis of CSF cell-free DNA has emerged as a new diagnostic tool for PCNSL. Treatment options have likewise evolved, with mature data from first-line chemotherapy-based prospective trials disclosing excellent results in younger (< 60–65) patients, with a cure achieved in a majority. However, results in older patients remain dismal, with several new salvage options under investigation including BTK pathway-targeted therapies, and CAR-T cell treatments. Meanwhile, low-dose radiation has emerged as an additional alternative for consolidation therapy.

Summary

For younger PCNSL patients, the goal of treatment is now a cure, with the next frontier being the development of therapies affording optimized neurocognitive outcome and lower toxicity. Treatment for older patients remains however an unmet need, with several promising clinical trials ongoing.
Literature
1.
Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–8.PubMedPubMedCentralCrossRef
2.
Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, et al. Trends in primary central nervous system lymphoma incidence and survival in the US. Br J Haematol. 2016;74(3):417–24.CrossRef
3.
Lv C, Wang J, Zhou M, Xu JY, Chen B, Wan Y. Primary central nervous system lymphoma in the United States, 1975–2017. Ther Adv Hematol. 2022;23(13):20406207211066170.CrossRef
4.
Kreisl TN, Panageas KS, Elkin EB, Deangelis LM, Abrey LE. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma. 2008;49(9):1710–6.PubMedCrossRef
5.
Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, et al. The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncol. 2018;20(5):687–94.PubMedCrossRef
6.
Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro-Oncol. 2019;21(3):296–305.PubMedCrossRef
7.
8.
Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, et al. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018;9(48):28897–902.PubMedPubMedCentralCrossRef
9.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol. 2021;23(8):1231–51.PubMedPubMedCentralCrossRef
10.
Kaulen LD, Galluzzo D, Hui P, Barbiero F, Karschnia P, Huttner A, et al. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. J Neurooncol. 2019;144(1):107–15.PubMedCrossRef
11.
Kaulen LD, Karschnia P, Dietrich J, Baehring JM. Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol. 2020;149(1):153–9.PubMedCrossRef
12.
Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177–86.PubMedCrossRef
13.
Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92(2):261–6.PubMedCrossRef
14.
15.
Bathla G, Dhruba DD, Soni N, Liu Y, Larson NB, Kassmeyer BA, et al. AI-based classification of three common malignant tumors in neuro-oncology: A multi-institutional comparison of machine learning and deep learning methods. J Neuroradiol. 2024;51(3):258–64.PubMedCrossRef
16.
Cassinelli Petersen GI, Shatalov J, Verma T, Brim WR, Subramanian H, Brackett A, et al. Machine learning in differentiating gliomas from primary CNS lymphomas: a systematic review, reporting quality, and risk of bias assessment. AJNR Am J Neuroradiol. 2022;43(4):526–33.PubMedPubMedCentralCrossRef
17.
Tariciotti L, Ferlito D, Caccavella VM, Di Cristofori A, Fiore G, Remore LG, et al. A deep learning model for preoperative differentiation of glioblastoma, brain metastasis, and primary central nervous system lymphoma: an external validation study. NeuroSci. 2023;4(1):18–30.CrossRef
18.
Krebs S, Barasch JG, Young RJ, Grommes C, Schöder H. Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. Ann Lymphoma. 2021;5:15.PubMedPubMedCentralCrossRef
19.
Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5034–43.CrossRef
20.
Barajas RF, Politi LS, Anzalone N, Schöder H, Fox CP, Boxerman JL, et al. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncol. 2021;23(7):1056–71.PubMedPubMedCentralCrossRef
21.
Camilleri-Broët S, Crinière E, Broët P, Delwail V, Mokhtari K, Moreau A, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–6.PubMedCrossRef
22.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.PubMedCrossRef
23.
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42(3):279–90.PubMedCrossRef
24.
Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–29.PubMedPubMedCentralCrossRef
25.
Yamagishi Y, Sasaki N, Nakano Y, Matushita Y, Omura T, Shimizu S, et al. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. Cancer Sci. 2021;112(11):4702–10.PubMedPubMedCentralCrossRef
26.
Yamada S, Ishida Y, Matsuno A, Yamazaki K. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015;56(7):2141–5.PubMedCrossRef
27.
Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A, et al. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review. Neuro-Oncol. 2024;26(6):993–1011.PubMedCrossRef
28.
Herzi D, Le Garff-Tavernier M, Sourdeau E, Choquet S, Soussain C, Nichelli L, et al. Prognostic value of CSF IL-10 at early assessment of induction chemotherapy in primary CNS lymphomas: a LOC network study. Neurology. 2024;102(12):e209527.PubMedCrossRef
29.
Calimeri T, Anzalone N, Cangi MG, Fiore P, Gagliardi F, Miserocchi E, et al. Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10. Lancet Haematol. 2024;11(7):e540–9.PubMedCrossRef
30.
Ferreri AJM, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(2):266–72.CrossRef
31.
Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(36):5711–5.CrossRef
32.
Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31(1):100–5.
33.
Jahr G, Da Broi M, Holte H, Beiske K, Meling TR. The role of surgery in intracranial PCNSL. Neurosurg Rev. 2018;41(4):1037–44.PubMedCrossRef
34.
Chojak R, Koźba-Gosztyła M, Polańska K, Rojek M, Chojko A, Bogacz R, et al. Surgical resection versus biopsy in the treatment of primary central nervous system lymphoma: a systematic review and meta-analysis. J Neurooncol. 2022;160(3):753–61.PubMedPubMedCentralCrossRef
35.
Rae AI, Mehta A, Cloney M, Kinslow CJ, Wang TJC, Bhagat G, et al. Craniotomy and survival for primary central nervous system lymphoma. Neurosurgery. 2019;84(4):935–44.PubMedCrossRef
36.
Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496–502.PubMedCrossRef
37.
Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol. 2010;85(6):520–8.PubMedCrossRef
38.
Scheichel F, Marhold F, Pinggera D, Kiesel B, Rossmann T, Popadic B, et al. Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study. BMC Cancer. 2021;29(21):754.CrossRef
39.
Velasco R, Mercadal S, Vidal N, Alañá M, Barceló MI, Ibáñez-Juliá MJ, et al. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol. 2020;148(3):545–54.PubMedCrossRef
40.
Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17.PubMedCrossRef
41.
Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005;62(3):809–13.PubMedCrossRef
42.
Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88–06. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(2):556–64.CrossRef
43.
O’Neill BP, Wang CH, O’Fallon JR, Colgan JD, Earle JD, Krigel RL, et al. Primary central nervous system non-Hodgkin’s lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86–72-52. Int J Radiat Oncol Biol Phys. 1999;43(3):559–63.PubMedCrossRef
44.
Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994;81(2):188–95.PubMedCrossRef
45.
Ferreri AJ, Reni M, Dell’Oro S, Ciceri F, Bernardi M, Camba L, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology. 2001;60(2):134–40.PubMedCrossRef
46.
Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(28):4570–4.CrossRef
47.
Suzuki Y, Imoto N, Ishihara S, Fujiwara S, Ito R, Sakai T, et al. A retrospective analysis of R-MPV plus response-adapted whole-brain radiotherapy for elderly patients with primary central nervous system lymphoma. Intern Med Tokyo Jpn. 2022;61(9):1345–52.CrossRef
48.
Omuro AMP, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62(10):1595–600.PubMedCrossRef
49.
Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47.PubMedCrossRef
50.
Omuro AMP, DeAngelis LM, Karrison T, Bovi JA, Rosenblum M, Corn BW, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). J Clin Oncol. 2020;38(15_suppl):2501–2501.CrossRef
51.
Schaff LR, Lobbous M, Carlow D, Schofield R, Gavrilovic IT, Miller AM, et al. Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. BMC Cancer. 2022;13(22):60.CrossRef
52.
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251-259.PubMedCrossRef
53.
Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-227.PubMedCrossRef
54.
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216–28.PubMedCrossRef
55.
Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(25):3061–8.CrossRef
56.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10.PubMedPubMedCentralCrossRef
57.
Therkelsen KE, Schaff LR, Nandakumar S, Omuro AMP, DeAngelis LM, Grommes C. Long-term outcomes in primary CNS lymphoma after R-MVP and high-dose chemotherapy with autologous hematopoietic stem cell transplant. Neurology. 2023;101(7):e710–6.PubMedPubMedCentralCrossRef
58.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36(7):1870–8.PubMedCrossRef
59.
Houillier C, Taillandier L, Houot R, Chinot O, Molucon-Chabrot C, Schmitt A, et al. Radiotherapy (WBRT) or Autologous Stem-Cell Transplantation (ASCT) for primary CNS lymphoma in patients 60 years of age and younger: long-term results of the intergroup anocef-goelams randomized phase II precis study. Blood. 2021;138(Supplement 1):658.CrossRef
60.
Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Moluçon-Chabrot C, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol. 2022;40(32):3692–8.PubMedCrossRef
61.
Houillier C, Choquet S, Touitou V, Martin-Duverneuil N, Navarro S, Mokhtari K, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology. 2015;84(3):325–6.PubMedCrossRef
62.
Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595–607.PubMedPubMedCentralCrossRef
63.
Vu K, Rubenstein J, Mannis GN, Hwang J, Geng H. Low-dose lenalidomide maintenance after induction therapy in older patients with primary CNS lymphoma. Blood. 2018;132(Supplement 1):4230.CrossRef
64.
Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–45.PubMedPubMedCentralCrossRef
65.
Bairey O, Taliansky A, Glik A, Amiel A, Yust-Katz S, Gurion R, et al. A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer. 2023;129(24):3905–14.PubMedCrossRef
66.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. Accessed June 5, 2024.
67.
Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-Oncol. 2016;18(9):1297–303.PubMedPubMedCentralCrossRef
68.
Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, et al. Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report. Ann Oncol. 2007;18(11):1851–5.PubMedCrossRef
69.
Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81.PubMedPubMedCentralCrossRef
70.
Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3.PubMedPubMedCentralCrossRef
71.
Yi JH, Kim SJ, Kim SA, Jung J, Yoon DH. Nivolumab in relapsed or refractory primary CNS lymphoma: multicenter, retrospective study. Blood. 2023;142(Supplement 1):1772.CrossRef
72.
Hoang-Xuan K, Houot R, Soussain C, Blonski M, Schmitt A, Delwail V, et al. First results of the Acsé Pembrolizumab phase II in the primary CNS lymphoma (PCNSL) cohort. Blood. 2020;136(Supplement 1):15–6.CrossRef
73.
Davis RE, Ngo VN, Lenz G, Tolar P, Young R, Romesser PB, et al. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature. 2010;463(7277):88–92.PubMedPubMedCentralCrossRef
74.
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton Tyrosine Kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-Cell malignancies. J Clin Oncol. 2013;31(1):88–94.PubMedCrossRef
75.
76.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro-Oncol. 2021;23(1):122–33.PubMedCrossRef
77.
Asai K, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, et al. Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. J Clin Oncol. 2023;41(16_suppl):7548–7548.CrossRef
78.
Linton K, Doorduijn J, El-Sharkawi D, Mous R, Forconi F, Lewis D, et al. PB2331: An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s Tyrosine Kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies. HemaSphere. 2023;7(Suppl):e29005fd.PubMedCentralCrossRef
79.
Von Roemeling C, Iqbal M, Doonan B, Hoang-Minh L, Klippel K, Tun H, et al. P1298: The IRAK-4 inhibitor emavusertib (CA-4948) for the treatment of primary CNS lymphoma. HemaSphere. 2022;6(Suppl):1183–4.CrossRef
80.
Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, et al. Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases. Clin Cancer Res. 2023;29(9):1751–62.CrossRef
81.
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107(9):3716–23.PubMedPubMedCentralCrossRef
82.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective “proof of concept” phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(4):621–8.CrossRef
83.
Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240–8.PubMedPubMedCentralCrossRef
84.
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978–92.PubMedCrossRef
85.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2022;7(1):32–9.PubMedCentralCrossRef
Metadata
Title
Advances in Primary Central Nervous System Lymphoma
Authors
Kate E. Therkelsen
Antonio Omuro
Publication date
25-11-2025

Other articles of this Issue 1/2025

Drug Treatments for Neurodevelopmental Disorders: Targeting Signaling Pathways and Homeostasis

Intracranial pressure crisis

How do you identify apraxia?

The Spectrum of Movement Disorders Associated with Systemic Lupus Erythematosus

Correction to: Improving Indigenous Stroke Outcomes by Shifting Our Focus from Health to Cultural Literacy

  • Correction

Pathophysiology and Management of Refractory Trigeminal Neuralgia

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits